It has been evaluated in the PHOEBE phase III clinical trial [70] with 267 patients with HER2-positive advanced breast cancer previously treated with trastuzumab and taxanes and/or anthracyclines to receive pyrotinib or lapatinib with capecitabine. Here, ERBB2 is linked to breast carcinoma.